Clinical Trial Update: A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors [Phase 2]

View source ↗

Summary

Phase II study of SHR-4602 as monotherapy or in combination with other anti-tumor therapies for advanced solid tumors; the trial status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• SHR-4602

Snippet

Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Conditions: Advanced Solid Tumors | Phase 2 | Status: NOT_YET_RECRUITING